Evidence map›Paper›PMID 36700217›Full record

ArticleFrontiers in immunology2022

Retrospective analysis on the immunopotentiating mechanism of an emulsion-based vaccine adjuvant on human antigen presenting cells.

Srinivasa Reddy Bonam, Peter Paul Platenburg, Jagadeesh Bayry

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in immunology · 2025
    Article
  4. Vaccine adjuvants for infectious disease in the clinic.Bioengineering & translational medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Srinivasa Reddy BonamInstitut National de la Santé et de la Recherche Médicale, Centre de Recherche desCordeliers, Sorbonne Université, Université de Paris, Paris, France.
Peter Paul PlatenburgLiteVax B.V., Oss, Netherlands.
Jagadeesh BayryInstitut National de la Santé et de la Recherche Médicale, Centre de Recherche desCordeliers, Sorbonne Université, Université de Paris, Paris, France.
Centre de Recherche des Cordeliers · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We retrospectively analyzed the immunopotentiating mechanism of an oil-in-water (O/W) emulsion-based vaccine adjuvant LiteVax™ Adjuvant (LVA) that contains CMS (Maltose 4'-monosulphate 1,2,3,6,2',3',6'-heptadecanoic acid ester), squalane, Tween 80 in phosphate buffered saline. Despite being effective in animal models, the immunological mechanisms by which LVA exerts adjuvant function are not known. As dendritic cells (DC) are key for initiating and propagating the immune response, we have investigated the effect of LVA and of its components on the DC function. We show that CMS but not LVA significantly enhances the expression of DC activation-associated markers, cytokine secretion, and CD4

Indexed as

Adjuvants, VaccineAntigen-Presenting CellsAdjuvants, ImmunologicAdjuvants, PharmaceuticAnimalsEmulsionsHumansRetrospective StudiesAdjuvants, ImmunologicAdjuvants, PharmaceuticAdjuvants, VaccineEmulsionsadjuvantantigen presenting cell (APC)CD4+ T cellCMScytokinesdendritic cellshumanoil-in-water emulsion

Identifiers

PMID36700217
PMCPMC9868768
OpenAlexW4313889087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.